medline.ch Onkologie Urologische Tumoren

	CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer. Cancer Biomark Su Z, Wang G, Li L. PMID: 37781794 [PubMed - as supplied by publisher]
	Sulforaphane and bladder cancer: a potential novel antitumor compound. Front Pharmacol Zuo M, Chen H, Liao Y, He P, Xu T, Tang J, Zhang N. PMID: 37781700 [PubMed - as supplied by publisher]
	Gastrointestinal/genitourinary adverse event after intensity modulated versus three-dimensional primary radiation therapy in the treatment of prostate cancer: systematic review and meta-analysis. J Cancer Guo W, Sun YC, Zhang LY, Yin XM. PMID: 37781069 [PubMed]
	Dietary inflammatory index and renal cancer risk: a prospective study. Food Funct Wu J, Yu C, Shivappa N, Hébert JR, Xu X. PMID: 37779467 [PubMed - as supplied by publisher]
	Comparison of 18F-PSMA-1007 and 18F-Choline PET/CT in prostate cancer patients with biochemical recurrence: a phase 3, prospective, multicenter, randomized study. Nucl Med Commun Panagiotidis E, Fragkiadaki V, Papathanasiou N, Kypraios C, Liatsikos E, Klampatsas A, Paschali A, Exarhos D, Zarokosta F, Chatzipavlidou V, Apostolopoulos D, Datseris I. PMID: 37779440 [PubMed - as supplied by publisher]
	Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study. Eur J Hybrid Imaging Murthy V, Appiah-Kubi E, Nguyen K, Thin P, Hotta M, Shen J, Drakaki A, Rettig M, Gafita A, Calais J, Sonni I. PMID: 37779132 [PubMed]
	The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial. Eur Urol Light A, Kanthabalan A, Otieno M, Pavlou M, Omar R, Adeleke S, Giganti F, Brew-Graves C, Williams NR, Emara A, Haroon A, Latifoltojar A, Sidhu H, Freeman A, Orczyk C, Nikapota A, Dudderidge T, Hindley RG, Virdi J, Arya M, Payne H, Mitra AV, Bomanji J, Winkler M, Horan G, Moore CM, Emberton M, Punwani S, Ahmed HU, Shah TT. PMID: 37778954 [PubMed - as supplied by publisher]
	Improved Value of Multiplexed Sensitivity Encoding DWI with Reversed Polarity GradientsÂ in Diagnosing Prostate Cancer: A Comparison Study with Single-Shot DWI and MUSE DWI. Acad Radiol Zhao W, Ju S, Yang H, Wang Q, Fang L, Pylypenko D, Wang W. PMID: 37778902 [PubMed - as supplied by publisher]
	Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer. BMC Urol Gandaglia G, Leni R, Plagakis S, Stabile A, Montorsi F, Briganti A. PMID: 37777767 [PubMed - as supplied by publisher]
	A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT). BMC Cancer Wolfe S, Diven MA, Marciscano AE, Zhou XK, Kishan AU, Steinberg ML, Miccio JA, Camilleri P, Nagar H. PMID: 37777738 [PubMed - as supplied by publisher]
	Active surveillance should be considered for select men with Grade Group 2 prostate cancer. BMC Urol Pekala KR, Bergengren O, Eastham JA, Carlsson SV. PMID: 37777716 [PubMed - as supplied by publisher]
	Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial. Eur Urol Rosellini M, Tassinari E, Marchetti A, Mollica V, Massari F. PMID: 37777426 [PubMed - as supplied by publisher]
	Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment. J Immunother Cancer Song Y, Peng Y, Qin C, Wang Y, Yang W, Du Y, Xu T. PMID: 37777251 [PubMed - indexed for MEDLINE]
	Role of exosomes in prostate cancer and male fertility. Drug Discov Today Dey D, Ghosh S, Mirgh D, Parsad Panda S, Kumar Jha N, Kumar Jha S. PMID: 37777169 [PubMed - as supplied by publisher]
	Effects of curcumin and ursolic acid in prostate cancer: A systematic review. Urologia Besasie BD, Saha A, DiGiovanni J, Liss MA. PMID: 37776274 [PubMed - as supplied by publisher]
	Scales for Assessing Male Sexual Function are not Entirely Applicable to Gay and Bisexual Men with Prostate Cancer. Urol Clin North Am Mainwaring JM, Lee TK, Wassersug RJ, Wibowo E. PMID: 37775214 [PubMed - as supplied by publisher]
	Does Radical Local Treatment in oligometastatic Prostate Cancer improve Overall Survival- A systematic review and meta-analysis. Urology Madhavan K, Jena R, Viswas MR, Kaushal D, Deen S, Rustagi S, Cahill D, Sooriakumaran P. PMID: 37774847 [PubMed - as supplied by publisher]
	Do Swiss urologists and Swiss internists screen themselves and their relatives for prostate cancer? A questionnaire study. Swiss Med Wkly Scherer TP, Saba K, Wettstein MS, Lucca I, Mortezavi A, Waisbrod S, Aujesky D, Capaul R, Strebel RT. PMID: 37774392 [PubMed - indexed for MEDLINE]
	The Association of P53, CK29, and FGFR3 Overexpression with the Characteristics of Urothelial Cell Carcinoma of the Bladder. Asian Pac J Cancer Prev Asgari M, Firouzi F, Abolhasani M, Bahadoram M, Barahman M, Madjd Z, Mehrazam M, Hassanzadeh S, Akade E. PMID: 37774064 [PubMed - indexed for MEDLINE]
	Survival Rate and Prognostic Factors of Localised Prostate Cancer in Southeast Asian Countries: A Systematic Review with Meta-Analysis. Asian Pac J Cancer Prev Mohammed Nawi A, Masdor NA, Othman R, Kandayah T, Ahmad N, Safian N. PMID: 37774044 [PubMed - as supplied by publisher]

Artikel 1 - 20 / 156377

Seite 1 von 7819

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung